Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.
about
Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.Using Drosophila models of neurodegenerative diseases for drug discovery.Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.
P2860
Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@ast
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@en
type
label
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@ast
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@en
prefLabel
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@ast
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@en
P2860
P356
P1476
Targeting aggregation in the d ...... polyglutamine repeat diseases.
@en
P2093
Joan S Steffan
Leslie Michels Thompson
P2860
P304
P356
10.1517/14728222.7.2.201
P407
P577
2003-04-01T00:00:00Z